Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada; Eberhard-Karls-University, Tuebingen, Germany; Clinical Trial Unit Studienpraxis Urologie, Nürtingen, Germany.
Decipher Biosciences, Vancouver, Canada.
Urol Oncol. 2021 Aug;39(8):498.e1-498.e11. doi: 10.1016/j.urolonc.2021.04.011. Epub 2021 Jun 1.
Carbonic anhydrase IX (CA9) is important in the regulation of intra- and extracellular pH in solid tumors, contributing to cell growth and invasion. In urothelial carcinoma (UC), CA9 has been identified as a urinary marker for disease detection, but its biologic role is unknown. To date, differential gene expression patterns of CA9 in various molecular subtypes and potential effects of CA9 inhibition in UC cells are unknown. We aimed to investigate the function of CA9 and the effects of CA9 inhibition in invasive UC.
Immunohistochemistry was used to assess CA9 expression in a cohort of 153 patients undergoing radical cystectomy. CA9 expression was correlated with molecular subtype by analysis of the TCGA data and of our own cohort of 223 patients with invasive UC receiving neoadjuvant chemotherapy. CA9 expression was assessed in a panel of 12 UC cell lines by Western Blot and qPCR, and multiple siRNAs were used to silence CA9 in 2 cell lines. Effects of CA9 silencing on cell growth, migration, and invasion were assessed. We also used the small molecule inhibitor U-104 to inhibit CA9 in vitro and in an orthotopic xenograft model.
CA9 expression was higher in cancer tissue compared to benign urothelium and was particularly highly expressed in luminal papillary and basal squamous tumors. CA9 expression did not correlate with outcome after neoadjuvant chemotherapy and/or radical cystectomy. Silencing of CA9 by siRNA diminished invasion but did not induce a consistent change of cell growth and migration. Treatment with U-104 led to cell growth reduction only at high concentrations in vitro and failed to have a significant effect on tumor growth in vivo.
The present study confirms over-expression of CA9 in UC and for the first time shows a correlation with molecular subtypes. However, CA9 expression showed no association with the outcome of patients with muscle invasive bladder cancer and inhibition of CA9 did not lead to a consistent inhibition of tumor growth. Based on these data, CA9 exhibits a role neither as a predictive or prognostic marker nor as a therapeutic target in invasive UC.
碳酸酐酶 9(CA9)在实体瘤细胞内外 pH 值调节中起着重要作用,促进细胞生长和侵袭。在尿路上皮癌(UC)中,CA9 已被确定为疾病检测的尿标志物,但它的生物学作用尚不清楚。迄今为止,CA9 在各种分子亚型中的差异基因表达模式及其在 UC 细胞中的抑制作用尚不清楚。我们旨在研究 CA9 的功能及其在侵袭性 UC 中的抑制作用。
免疫组织化学用于评估 153 例接受根治性膀胱切除术的患者中的 CA9 表达。通过 TCGA 数据和我们自己的 223 例接受新辅助化疗的侵袭性 UC 患者队列的分析,CA9 表达与分子亚型相关。通过 Western Blot 和 qPCR 评估 12 种 UC 细胞系中的 CA9 表达,并使用多种 siRNA 沉默 2 种细胞系中的 CA9。评估 CA9 沉默对细胞生长、迁移和侵袭的影响。我们还使用小分子抑制剂 U-104 在体外和原位异种移植模型中抑制 CA9。
CA9 在癌症组织中的表达高于良性尿路上皮,在腔乳头状和基底鳞状肿瘤中表达尤其高。CA9 表达与新辅助化疗和/或根治性膀胱切除术后的结果无关。siRNA 沉默 CA9 可减少侵袭,但不会导致细胞生长和迁移的一致变化。在体外,U-104 的治疗仅在高浓度下导致细胞生长减少,并且在体内对肿瘤生长没有显著影响。
本研究证实 CA9 在 UC 中过度表达,并首次显示与分子亚型相关。然而,CA9 表达与肌肉浸润性膀胱癌患者的结局无关,抑制 CA9 并不能一致抑制肿瘤生长。基于这些数据,CA9 既不是侵袭性 UC 的预测或预后标志物,也不是治疗靶点。